Truist Securities Maintains Hold on Globus Medical, Raises Price Target to $68
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Richard Newitter maintains a 'Hold' rating on Globus Medical (NYSE:GMED) and raises the price target from $64 to $68.
July 19, 2023 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The 'Hold' rating by Truist Securities on Globus Medical is maintained and the price target is raised from $64 to $68.
The news is directly about Globus Medical and its rating by Truist Securities. The 'Hold' rating suggests that the stock is expected to perform in line with the market or the sector in the next 12 months. The increase in price target indicates a positive outlook, but as the rating is 'Hold', it is not expected to have a significant impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100